Global Long QT Syndrome Market Research Report, Type (LQT1, LQT2, LQT3), Diagnosis (Tests, ECG, Genetic Testing), Treatment (Medications, Surgical Procedures), End Users (Hospitals, Diagnostic Labs, Research Organizations) - Global Forecast till 2023

Market Scenario

Long QT syndrome (LQTS) is a disorder of the heart's electrical activity, leading to irregular heartbeats. Fainting and seizures are the most common symptoms for this disease. In most of the patients, the first sign/symptom of the disease appears after the age of 40. Moreover, it is estimated that the risks for the disease increase with pre-existing conditions of cardiovascular disease, diabetes besides others. Therefore, factors such as increasing prevalence of the cardiovascular diseases, diabetes, and the growing geriatric population are the major drivers that are estimated to drive the market growth during the forecast period. According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. Furthermore, the World Health Organization in 2016 reported that an estimated 422 million adults across the world were living with diabetes in 2014. Additionally, it was estimated that deaths due to diabetes were higher in the low and middle income countries as compared to the high income countries. Rising per capita healthcare expenditure and increasing R&D expenses by key players of the market is fuelling the market growth. However, factors such as lack of awareness for this syndrome, stringent FDA approvals and high cost of the surgical therapeutics for the treatment of this disorder are restraining the market growth.

The global long QT syndrome market is expected to grow at a CAGR of 8.50% during forecast period.

Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1: Global Long QT Syndrome Market Share, by Region
The global long QT syndrome market is segmented on the basis of type, diagnosis, treatment, and end users.

On the basis of the type, the market is segmented into long QT syndrome type 1, long QT syndrome type 2, long QT syndrome type 3, and others.

On the basis of the diagnosis, the market is categorised into tests, electrocardiogram (ECG), genetic testing, and others. The test segment is further segmented into serum potassium level tests, magnesium level tests, and others. The ECG segment is further segmented into holter monitor, event monitor, and others.

On the basis of the treatment, the market is segmented into medication, surgical procedures, and others. The medication segment is sub-segmented into beta blockers, mexiletine, and others. The beta blockers segment, by medication, is further segmented into nadolol, propranolol, and others. The surgical procedures segment is segmented into left cardiac sympathetic denervation surgery, implantable cardioverter-defibrillator (ICD), and others.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic labs, research organizations, and others.

The key players for the global long QT syndrome market are Invitae Corporation (U.S.), GeneDx. (U.S.), Asper Biogene (Estonia), Boston Scientific Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), Pfizer Inc. (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Aralez Pharmaceuticals Inc. (Canada), AstraZeneca (U.K), Torrent Pharmaceuticals Limited (India), Lupin Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), and others.

Research Methodology
Regional Analysis:

Americas dominate the global long QT syndrome market owing to a well-developed healthcare sector and high per capita healthcare expenditures. Apart from this, increasing number of patients suffering from cardiovascular diseases and diabetes as a result of changing lifestyle are estimated to drive the market growth in the Americas.

Europe is the second largest long QT syndrome market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, and government support for research & development will drive the market. In 2017, according to the British Heart Foundation, about 2,265,422 cases of coronary heart diseases were registered from 2015 to 2016 in the U.K. Moreover, it was estimated that in 2015, the cost of cardiovascular diseases in the U.K was about USD 18 billion.

Asia Pacific is the fastest growing region for the market due to the presence continuously developing economies, and presence of huge opportunity in the market. Increasing prevalence of diabetes and growing geriatric population are the factors boosting the market growth within the region. According to the World Health Organization, the prevalence of diabetes in the Western Pacific region is increasing and approximately 71,050,100 individuals are estimated to suffer from diabetes by 2030.

On the other hand, the Middle East & Africa has the least share in the global long QT syndrome market due to presence of poor economies and stringent government policies especially in the African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the developed economies like Qatar, Dubai and others.
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Long QT Syndrome Market, by Type
6.1 Introduction
6.2 Long QT Syndrome Type 1 (LQT1) Market Estimates & Forecast, 2017 – 2023
6.3 Long QT Syndrome Type 2 (LQT2) Market Estimates & Forecast, 2017 – 2023
6.4 Long QT Syndrome Type 3 (LQT3) Market Estimates & Forecast, 2017 – 2023
6.5 Others

Chapter 7. Global Long QT Syndrome Market, by Diagnosis
7.1 Introduction
7.2 Tests Market Estimates & Forecast, 2017 – 2023
7.2.1 Serum Potassium Level Tests
7.2.2 Magnesium Level Tests
7.2.3 Others
7.3.1 Holter Monitor
7.3.2 Event Monitor
7.3.3 Others
7.5 Others

Chapter 8. Global Long QT Syndrome Market, by Treatment
8.1 Introduction
8.2 Medications
Market Estimates & Forecast, 2017 – 2023
8.2.1 Beta Blockers
8.2.1.1 Nadolol
8.2.1.2 Propranolol
8.2.1.3 Others
8.2.2 Mexiletine
8.2.3 Others

8.3 Surgical Procedures
Market Estimates & Forecast, 2017 – 2023
8.3.1 Left Cardiac Sympathetic Denervation Surgery
8.3.2 Implantable Cardioverter-Defibrillator (ICD)
8.3.3 Others
8.4 Others

Chapter 9 Global Long QT Syndrome Market, by End User
9.1 Introduction
9.2 Hospitals & Clinics
Market Estimates & Forecast, 2017 – 2023
9.3 Diagnostic Labs
Market Estimates & Forecast, 2017 – 2023
9.4 Research Organizations
Market Estimates & Forecast, 2017 – 2023
9.5 Others

Chapter 10. Global Long QT Syndrome Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

Chapter 12 Company Profiles
12.1 Aralez Pharmaceuticals Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Asper Biogene
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 AstraZeneca
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Boston Scientific Corporation
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Cipla Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 GeneDx.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
Chapter 13 MRFR Conclusion

13.1 Key Findings
13.1.1 From CEO's View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Long QT Syndrome Industry

Chapter 14 Appendix

LIST OF TABLES
Table 1 Long QT Syndrome Industry Synopsis, 2017 – 2023
Table 2 Global Long QT Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Long QT Syndrome Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 5 Global Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 6 Global Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 7 Global Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 8 North America Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 9 North America Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 10 North America Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 11 North America Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 12 U.S. Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 13 U.S. Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 U.S. Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 15 U.S. Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 16 Canada Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 17 Canada Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 18 Canada Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 19 Canada Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 20 South America Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 21 South America Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 23 South America Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 24 Europe Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 25 Europe Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Europe Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Europe Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 28 Western Europe Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 29 Western Europe Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 30 Western Europe Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 31 Western Europe Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)
Table 40 Middle East & Africa Long QT Syndrome Market by Type, 2017 – 2023, (USD Million)
Table 41 Middle East & Africa Long QT Syndrome Market by Diagnosis, 2017 – 2023, (USD Million)
Table 42 Middle East & Africa Long QT Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 43 Middle East & Africa Long QT Syndrome Market by End User, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Long QT Syndrome Market
Figure 3 Market Dynamics for Global Long QT Syndrome Market
Figure 4 Global Long QT Syndrome Market Share, by Type 2016
Figure 5 Global Long QT Syndrome Market Share, by Diagnosis 2016
Figure 6 Global Long QT Syndrome Market Share, by Treatment 2016
Figure 7 Global Long QT Syndrome Market Share, by End User, 2016
Figure 8 Global Long QT Syndrome Market Share, by Region, 2016
Figure 9 North America Long QT Syndrome Market Share, by Country, 2016
Figure 10 Europe Long QT Syndrome Market Share, by Country, 2016
Figure 11 Asia Pacific Long QT Syndrome Market Share, by Country, 2016
Figure 12 Middle East & Africa Long QT Syndrome Market Share, by Country, 2016
Figure 13 Global Long QT Syndrome Market: Company Share Analysis, 2016 (%)
Figure 14 Aralez Pharmaceuticals Inc.: Key Financials
Figure 15 Aralez Pharmaceuticals Inc.: Segmental Revenue
Figure 16 Aralez Pharmaceuticals Inc.: Geographical Revenue
Figure 17 Asper Biogene: Key Financials
Figure 18 Asper Biogene: Segmental Revenue
Figure 19 Asper Biogene: Geographical Revenue
Figure 20 AstraZeneca: Key Financials
Figure 21 AstraZeneca: Segmental Revenue
Figure 22 AstraZeneca: Geographical Revenue
Figure 23 Boston Scientific Corporation: Key Financials
Figure 24 Boston Scientific Corporation: Segmental Revenue
Figure 25 Boston Scientific Corporation: Geographical Revenue
Figure 26 Cipla Inc.: Key Financials
Figure 27 Cipla Inc.: Segmental Revenue
Figure 28 Cipla Inc.: Geographical Revenue
Figure 29 GeneDx.: Key Financials
Figure 30 GeneDx.: Segmental Revenue
Figure 31 GeneDx.: Geographical Revenue
Figure 32 Invitae Corporation: Key Financials
Figure 33 Invitae Corporation: Segmental Revenue
Figure 34 Invitae Corporation: Geographical Revenue
Figure 35 Laboratory Corporation of America Holdings: Key Financials
Figure 36 Laboratory Corporation of America Holdings: Segmental Revenue
Figure 37 Laboratory Corporation of America Holdings: Geographical Revenue
Figure 38 Lupin Pharmaceuticals, Inc.: Key Financials
Figure 39 Lupin Pharmaceuticals, Inc.: Segmental Revenue
Figure 40 Lupin Pharmaceuticals, Inc.: Geographical Revenue
Figure 41 Mylan N.V.: Key Financials